Skip to content
Screener

Leonardo DRS, Inc. DRS ASC — Total company-funded independent research and development

Other segment segments

IMS
$7M+40.0%

Similar metrics at other companies

CorMedix logo
CRMDOther research and development — Total research and development
$4.87M+133%
Disc Medicine logo
IRONInternal Research And Development — Research And Development Expense
$11.31M+67.6%
Keysight Technologies logo
KEYSTotal segments — Research and Development Expense
$303M+27.3%
Beam Therapeutics logo
BEAMExternal Research And Development Expenses — Research And Development Expense
$30.08M-12.6%
Solid Biosciences Inc. logo
SLDBInternal Research And Development Expense — Research And Development Expense
$9.06M+33.9%
Fulgent Genetics, Inc. logo
FLGTTherapeutic Development — Research And Development Expense
$4.18M+4.7%

Other financials

Income statement

See full
Revenue$846.0M+5.9%
Gross profit$212.0M+17.1%
Operating income$77.0M+30.5%
Net income$62.0M+24.0%
EPS (diluted)$0.23+21.1%

Balance sheet

See full
Cash & equivalents$328.0M-13.7%
Total debt$170.0M-53.7%
Total equity$2.8B+7.7%
Total assets$4.2B+2.8%

Cash flow

See full
Operating cash flow-$66.0M+52.2%
CapEx$30.0M-6.3%
Free cash flow-$96.0M+43.5%

Valuation

See full
Market cap$11.91B+8.3%
Enterprise value$11.75B+6.1%
P/E41.1×-2.9×
P/S3.2×0.0×

Profitability

See full
Gross margin24.4%+1.5pp
Operating margin9.9%+0.7pp
Net margin7.8%+0.9pp
FCF margin8.1%—

Returns & leverage

See full
Return on equity10.9%+1.4pp
Debt / equity0.1×-0.1×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Leonardo DRS, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Leonardo DRS, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:36 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001833756-26-000025
(Dollars in millions)Three Months Ended March 31, 20262025
Corporate & Eliminations——
Total general and administrative$99$89
Company-funded independent research and development
ASC$24$23
IMS75
Corporate & Eliminations——
Total company-funded independent research and development$31$28
Amortization of acquired intangible assets

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is Leonardo DRS, Inc.'s ASC — total company-funded independent research and development?
Leonardo DRS, Inc. (DRS) reported ASC — total company-funded independent research and development of $24M in Q1 2026.
How has Leonardo DRS, Inc.'s ASC — total company-funded independent research and development changed year-over-year?
Leonardo DRS, Inc.'s ASC — total company-funded independent research and development increased by 4.3% year-over-year, from $23M to $24M.
What is the long-term trend for Leonardo DRS, Inc.'s ASC — total company-funded independent research and development?
Over 3 years (2022 to 2025), Leonardo DRS, Inc.'s ASC — total company-funded independent research and development has grown at a 33.2% compound annual growth rate (CAGR), from $44M to $104M.
What does ASC — total company-funded independent research and development mean?
Reflects the investment made by the company into internal research and development projects for the Advanced Sensing and Computing segment. These expenditures are aimed at developing new defense technologies and maintaining a competitive edge in sensing and computing domains.

Ask your AI about Leonardo DRS, Inc.'s asc — total company-funded independent research and development.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude